Research for anti-inflammatory therapeutic strategy against pulmonary fibrosis

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09546
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Collagenous pathology/Allergology
• Research Institution: Gunma University
• Principal Investigator: HISADA Takeshi 群馬大学, 医学部附属病院, 講師 (10344938)
• Co-Investigator(Renkei-kenkyūsha): OKAJIMA Fumikazu 青森大学, 薬学部, 教授 (30142748)
• Research Collaborator: YATOMI Masakiyo 群馬大学, 医学部附属病院, 助教 (60784105) ; SAITO Haruka 群馬大学, 医学部附属病院, 医員 (80447268)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺線維症 / 脂質メディエーター / resolvin / 炎症収束 / 動物モデル / ω－３脂肪酸

Outline of Final Research Achievements

Pulmonary fibrosis is a destructive inflammatory disease with limited therapeutic options. Resolvin D1 (RvD1) displays potent anti-inflammatory, pro-resolving activity. We tested the hypothesis that 17(R)-RvD1 can provide a therapeutic benefit by reducing inflammation and pulmonary fibrosis. Mice were exposed to bleomycin (BLM) to induce pulmonary fibrosis, and were then treated with 17(R)-RvD1. Administration of 17(R)-RvD1 from the start of BLM treatment attenuated neutrophil alveolar infiltration, lung collagen content, and IL-1β, TGF-β1, CTGF, and type I collagen mRNA expression, along with subsequent reduction in histologically detectable fibrosis. The administration of 17(R)-RvD1 at the later fibrotic stage also improved the lung failure. These results suggest that 17(R)-RvD1 attenuates pulmonary fibrosis by promoting the resolution of neutrophilic inflammation and also provides pulmonary restoration. These data highlight the therapeutic potential of 17(R)-RvD1.

Free Research Field

アレルギー・膠原病